Skip to content

Citius Pharmaceuticals, Inc.: 10-Q filed 2026-08-14

What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2026-08-14 (fiscal Q3 2026): 48 published measures, 133 facts as tagged in accession 0001213900-26-090185.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q3 2026
Accession
0001213900-26-090185 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-30142,255,198USD
At 2025-09-30130,938,025USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-3066,346,742USD
At 2025-09-3053,410,425USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3066,613,132USD
At 2025-09-3067,550,178USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3017,007,523USD
At 2025-09-304,252,290USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-10-01 to 2026-06-30-22,986,413USD273
2024-10-01 to 2025-06-30-14,671,948USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,493,788USD91
2025-10-01 to 2026-06-307,105,197USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-10-01 to 2026-06-3042,741,646USD273
2024-10-01 to 2025-06-3017,509,194USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-10-01 to 2026-06-30-7,000,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-277,118,897USD
At 2025-09-30-238,804,129USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3026,169,589shares91
2025-10-01 to 2026-06-3023,343,869shares273
2025-04-01 to 2025-06-3011,006,896shares91
2024-10-01 to 2025-06-309,020,356shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3026,169,589shares91
2025-10-01 to 2026-06-3023,343,869shares273
2025-04-01 to 2025-06-3011,006,896shares91
2024-10-01 to 2025-06-309,020,356shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.34USD/shares91
2025-10-01 to 2026-06-30-1.64USD/shares273
2025-04-01 to 2025-06-30-0.8USD/shares91
2024-10-01 to 2025-06-30-3.27USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.34USD/shares91
2025-10-01 to 2026-06-30-1.64USD/shares273
2025-04-01 to 2025-06-30-0.8USD/shares91
2024-10-01 to 2025-06-30-3.27USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-107,347USD91
2025-10-01 to 2026-06-30-74,317USD273
2025-04-01 to 2025-06-30264,240USD91
2024-10-01 to 2025-06-30792,720USD273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,810,665USD91
2025-10-01 to 2026-06-3011,879,167USD273
2025-04-01 to 2025-06-302,719,674USD91
2024-10-01 to 2025-06-307,946,529USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-11,732,074USD91
2025-10-01 to 2026-06-30-52,946,068USD273
2025-04-01 to 2025-06-30-8,788,007USD91
2024-10-01 to 2025-06-30-30,088,299USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3043,331,363USD
At 2025-09-3027,934,473USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2026-04-01 to 2026-06-30198,333USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3051,649,351USD
At 2025-09-3044,914,740USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-308,037,899USD
At 2025-09-3013,693,692USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2026-06-309,346,796USD
At 2025-09-309,346,796USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-30686,235USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-3012,734,019USD91
2025-10-01 to 2026-06-3058,441,336USD273
2025-04-01 to 2025-06-308,788,007USD91
2024-10-01 to 2025-06-3030,088,299USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-06-3022,625,945USD
At 2025-09-3022,286,693USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,001,945USD91
2025-10-01 to 2026-06-305,495,268USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-04-01 to 2026-06-30491,843USD91
2025-10-01 to 2026-06-301,609,929USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,053,869USD91
2025-10-01 to 2026-06-304,287,106USD273
2025-04-01 to 2025-06-301,621,325USD91
2024-10-01 to 2025-06-307,514,888USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3027,452,570shares
At 2025-09-3018,067,744shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3017,007,523USD
At 2025-09-304,252,290USD
At 2025-06-306,089,126USD
At 2024-09-303,251,880USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30343,704,577USD
At 2025-09-30306,336,239USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2026-06-3075,908,456USD
At 2026-03-3169,084,553USD
At 2025-12-3193,467,970USD
At 2025-09-3077,527,600USD
At 2025-06-3067,560,930USD
At 2025-03-3163,575,792USD
At 2024-12-3168,919,459USD
At 2024-09-3074,101,830USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-30753,039USD
At 2025-09-30818,694USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-30766,957USD
At 2025-09-30813,273USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-3098,170,796USD
At 2025-09-30102,184,858USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-3025,913,962USD
At 2025-09-304,190,253USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2026-06-307,696,443USD
At 2025-09-307,770,760USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-12,026,607USD91
2025-10-01 to 2026-06-30-49,497,212USD273
2025-04-01 to 2025-06-30-8,939,632USD91
2024-10-01 to 2025-06-30-30,203,903USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-11,919,260USD91
2025-10-01 to 2026-06-30-49,422,895USD273
2026-01-01 to 2026-03-31-28,109,746USD90
2025-10-01 to 2025-12-31-9,393,889USD92
2025-04-01 to 2025-06-30-9,203,872USD91
2024-10-01 to 2025-06-30-30,996,623USD273
2025-01-01 to 2025-03-31-11,511,505USD90
2024-10-01 to 2024-12-31-10,281,246USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-8,862,843USD91
2025-10-01 to 2026-06-30-38,314,768USD273
2025-04-01 to 2025-06-30-8,789,872USD91
2024-10-01 to 2025-06-30-29,474,623USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,149,173USD91
2025-10-01 to 2026-06-3038,261,001USD273
2025-04-01 to 2025-06-304,447,008USD91
2024-10-01 to 2025-06-3014,626,882USD273

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-30231,732USD91
2025-10-01 to 2026-06-30420,301USD273
2025-04-01 to 2025-06-30172,262USD91
2024-10-01 to 2025-06-30172,262USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-294,533USD91
2025-10-01 to 2026-06-303,448,856USD273
2025-04-01 to 2025-06-30-151,625USD91
2024-10-01 to 2025-06-30-115,604USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-10-01 to 2026-06-30-74,317USD273
2024-10-01 to 2025-06-30792,720USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-10-01 to 2026-06-30303,644USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-10-01 to 2026-06-3025,268,094USD273
2024-10-01 to 2025-06-3016,509,194USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2026-06-30686,235USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2026-06-30339,252USD273
2024-10-01 to 2025-06-308,940,201USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2026-06-30-5,655,793USD273
2024-10-01 to 2025-06-305,166,831USD273

Inspect the source

Entity
Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured
2026-09-20T09:12:24.553Z
SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))